
## Alexandre Corthay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2164496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tackling cancer cell dormancy: Insights from immune models, and transplantation. Seminars in Cancer Biology, 2022, 78, 5-16.	4.3	9
2	Spatial Analysis For Histopathology: A Statistical Approach. , 2022, , .		0
3	Immunology according to Dembic: Preserving integrity is key. Scandinavian Journal of Immunology, 2022, 95, e13173.	1.3	0
4	Reactive Species from Two-Signal Activated Macrophages Interfere with Their Oxygen Consumption Measurements. Antioxidants, 2021, 10, 1149.	2.2	1
5	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
6	The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases. Scandinavian Journal of Immunology, 2020, 92, e12893.	1.3	6
7	Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Communications Biology, 2020, 3, 196.	2.0	27
8	Antibody combinations for optimized staining of macrophages in human lung tumours. Scandinavian Journal of Immunology, 2020, 92, e12889.	1.3	16
9	Structural characterization of bioactive heteropolysaccharides from the medicinal fungus Inonotus obliquus (Chaga). Carbohydrate Polymers, 2018, 185, 27-40.	5.1	48
10	Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics. Cancer Treatment Reviews, 2018, 63, 79-95.	3.4	34
11	Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation. Frontiers in Immunology, 2018, 9, 2520.	2.2	86
12	CD4+ T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs. Cancer Research, 2018, 78, 4573-4585.	0.4	61
13	Immune Cell Composition in Human Non-small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 3101.	2.2	202
14	Immune Class Regulation and Its Medical Significance Part II of a Report of a Workshop on Foundational Concepts of Immune Regulation. Scandinavian Journal of Immunology, 2017, 85, 242-250.	1.3	4
15	Immunological Tolerance. Part I of a Report of a Workshop on Foundational Concepts of Immune Regulation. Scandinavian Journal of Immunology, 2017, 85, 84-94.	1.3	11
16	Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette–GuA©rin (BCG) via Synergistic Activation of Innate Immune Receptors. Molecular Pharmaceutics, 2017, 14, 4098-4112.	2.3	28
17	Inflammatory Biomarkers for Cancer. , 2017, , 241-257.		0

18 Multi-staining registration of large histology images. , 2017, , .

9

ALEXANDRE CORTHAY

#	Article	IF	CITATIONS
19	Toll-Like Receptor Ligands and Interferon- $\hat{I}^3$ Synergize for Induction of Antitumor M1 Macrophages. Frontiers in Immunology, 2017, 8, 1383.	2.2	166
20	Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ. Frontiers in Immunology, 2017, 8, 1667.	2.2	13
21	Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity. Frontiers in Immunology, 2016, 7, 167.	2.2	16
22	Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an <i>In Situ</i> Inflammatory Immune Response. Cancer Research, 2016, 76, 6864-6876.	0.4	77
23	Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncolmmunology, 2016, 5, e1039763.	2.1	77
24	Rituximab efficiently depletes B cells in lung tumorsÂand normal lung tissue. F1000Research, 2016, 5, 38.	0.8	15
25	Does the Immune System Naturally Protect Against Cancer?. Frontiers in Immunology, 2014, 5, 197.	2.2	183
26	How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Frontiers in Immunology, 2014, 5, 174.	2.2	166
27	Molecular profiling of tumor-specific T <sub>H</sub> 1 cells activated in vivo. Oncolmmunology, 2013, 2, e24383.	2.1	13
28	A model for cancer-suppressive inflammation. Oncolmmunology, 2012, 1, 1146-1155.	2.1	64
29	Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood, 2012, 119, 2176-2177.	0.6	41
30	SH2D2A Modulates T Cell Mediated Protection to a B Cell Derived Tumor in Transgenic Mice. PLoS ONE, 2012, 7, e48239.	1.1	23
31	CS14-2. A cancer-protective role of inflammation. Cytokine, 2011, 56, 101.	1.4	0
32	Is Secretion of Tumourâ€ <b>s</b> pecific Antigen Important for Cancer Eradication by CD4 <sup>+</sup> T Cells? – Implications for Cancer Immunotherapy by Adoptive T Cell Transfer. Scandinavian Journal of Immunology, 2011, 73, 527-530.	1.3	11
33	Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature Communications, 2011, 2, 240.	5.8	251
34	Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells. Cancer Research, 2009, 69, 5901-5907.	0.4	49
35	Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA). Cellular Signalling, 2009, 21, 274-281.	1.7	21
36	How do Regulatory T Cells Work?. Scandinavian Journal of Immunology, 2009, 70, 326-336.	1.3	497

ALEXANDRE CORTHAY

#	Article	IF	CITATIONS
37	Cytokine profile of successful cancer immunosurveillance mediated by tumor-specific CD4+ T cells. Cytokine, 2009, 48, 48.	1.4	0
38	CD4+ T Cells Cooperate With Macrophages for Specific Elimination of MHC Class II-Negative Cancer Cells. , 2007, 590, 195-208.		15
39	A Three-cell Model for Activation of NaÃ <sup>-</sup> ve T Helper Cells. Scandinavian Journal of Immunology, 2006, 64, 93-96.	1.3	103
40	Systemic Autoimmune Disease Caused by Autoreactive B Cells That Receive Chronic Help from Ig V Region-Specific T Cells. Journal of Immunology, 2005, 175, 2391-2400.	0.4	48
41	Primary Antitumor Immune Response Mediated by CD4+ T Cells. Immunity, 2005, 22, 371-383.	6.6	383
42	Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation. Molecular Therapy, 2004, 9, 328-336.	3.7	63
43	Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunology, Immunotherapy, 2004, 53, 759-69.	2.0	11
44	Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus. Clinical and Experimental Immunology, 2003, 132, 209-215.	1.1	42
45	Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood, 2003, 102, 605-612.	0.6	39
46	Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how Dost-translational modification of proteins Gay be involved in autoimmune disease. Annals of Medicine, 2001, 33, 456-465.	1.5	37
47	Evaluation of the Percentage of Peripheral T Cells with Two Different T Cell Receptor α-Chains and of their Potential Role in Autoimmunity. Journal of Autoimmunity, 2001, 16, 423-429.	3.0	44
48	T lymphocytes are not required for the spontaneous development of entheseal ossification leading to marginal ankylosis in the DBA/1 mouse. Arthritis and Rheumatism, 2000, 43, 844.	6.7	57
49	Collagen-induced arthritis development requires αβ T cells but not γδT cells: studies with T cell-deficient (TCR mutant) mice. International Immunology, 1999, 11, 1065-1073.	1.8	88
50	Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. European Journal of Immunology, 1998, 28, 2580-2590.	1.6	156
51	The Matrigel Cytokine Assay. Protocol Exchange, 0, , .	0.3	2